Compounds > hepsulfam
Page last updated: 2024-08-26

hepsulfam and Leukopenia

hepsulfam has been researched along with Leukopenia in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Geller, RB; Grochow, LB; Janisch, L; Larson, RA; Milton, J; Ratain, MJ1
Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; Hendricks, CB; Lubejko, B; McGuire, WP; Rowinsky, EK; Sartorius, S1
Brown, TD; Havlin, KA; Koeller, JM; Kuhn, JG; Marshall, MV; Ravdin, PM; Rodriguez, G; Von Hoff, DD1

Trials

3 trial(s) available for hepsulfam and Leukopenia

ArticleYear
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
    Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Blast Crisis; Brain Diseases; Coma; Dose-Response Relationship, Drug; Electroencephalography; Female; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukopenia; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sulfonic Acids; Thrombocytopenia

1995
Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
    Cancer research, 1991, Nov-01, Volume: 51, Issue:21

    Topics: Adult; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukopenia; Male; Metabolic Clearance Rate; Neoplasms; Neutropenia; Sulfonic Acids; Thrombocytopenia

1991
A phase I clinical and pharmacokinetic trial of hepsulfam.
    Cancer research, 1991, Dec-01, Volume: 51, Issue:23 Pt 1

    Topics: Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Sulfonic Acids; Thrombocytopenia

1991